Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Will Samsung (or Facebook) Buy Nokia?
FB may want Nokia's inexpensive Windows phone technology for a bargain price to market their own new phone product.
http://www.ibtimes.com/articles/350200/20120608/nokia-rim-microsoft-apple-samsung-smartphone-android.htm
--------------------
Will Samsung Buy Nokia?
Analysis
By DAVID ZIELENZIGER: Subscribe to David's RSS feed
June 8, 2012 11:33 AM EDT
Shares of Nokia (NYSE: NOK), the onetime king of mobile phones, rose more than 7 percent Friday on speculation Samsung Electronics (Seoul: 5930), the current leader, might be eyeing a takeover.
In early activity, Nokia American Depositary Receipts rose as high as $3.07, giving the Finnish phone maker a market capitalization of $11 billion.
Samsung, the world's No. 1 phone maker appointed a new CEO this week, Kwon Oh-hyun, who oversaw its semiconductor lines into the No. 2 worldwide, behind only Intel (Nasdaq: INTC), the No. 1 chipmaker.
Decisions about acquisitions and the course of Samsung's mobile business will remain with Chairman Lee Kun-hee, the company said.
Another rumored suitor for Nokia is Facebook (Nasdaq: FB), the No. 1 social networking site, which raised $16 billion in its initial public offering last month. Acquiring a mobile phone maker like Nokia would put it squarely in the mobile platform business, which CEO Mark Zuckerberg acknowledged was a new frontier.
Indeed, just before the IPO, Zuckerberg personally handled the details of the pending $1 billion acquisition of private Instagram of San Francisco. The deal is intended to add more photo applications for mobile phones to Facebook's PC-based technology.
The U.S. Federal Trade Commission has said it will examine the Instagram deal. The cash-and-shares acquisition hasn't closed yet.
A Samsung-Nokia deal would clearly be a blow to Apple (Nasdaq: AAPL), the world's most valuable technology company, which lost its No. 1 smartphone lead to Samsung in the first quarter. Samsung phones now operate on the Android OS developed by Google (Nasdaq: GOOG), the No. 1 search engine which last month finally acquired Motorola Mobility holdings. Samsung as well has said it might also be open to Windows 8, the new OS from Microsoft (Nasdaq: MSFT), the world's biggest software company, scheduled for release in the second half of the year.
Nokia, whose CEO, Stephen Elop, is a former Micrsoft VP, has already linked itself to Windows, scrapping the largely European Symbian OS for Windows 7, with implementation of Windows 8 this year. Still, Elop in April warned Nokia's finances were questionable and that the company expects to report a loss for the first half of 2012.
Nokia and Microsoft already enjoy excellent technical relations. At the International Consumer Electronics Show in January, Microsoft CEO Steve Ballmer lauded the company and said it would enjoy Microsoft's full support.
Microsoft, which spent $8.5 billion for voice-communications provider Skype last year, hasn't expressed any interest in acquiring a phone maker, though.
Speculation about Nokia comes at the same time as talk about a possible takeover of BlackBerry developer Research in Motion (Nasdaq: RIMM), which last month hired investment bankers to provide strategic advice. New CEO Thorsten Heins has said RIM wants to survive as an independent company, but the move suggests the company could be for sale.
Indeed, activist investor Victor Alboini, owner of a stake just under 5 percent in RIM, said after the hiring of the Wall Street banks its BlackBerry lines ought to be sold, with operation of the network sold to an enterprise software company such as Microsoft or International Business Machines Corp. (NYSE: IBM).
Shares of RIM rose 3 cents to $10.76 on Friday, while shares of Microsoft gained 12 cents to $29.35.
See ya at $.05!!!!!
$LEE - "Buffett has said that the newspaper business overall is in trouble, but he's optimistic about small to mid-sized newspapers that provide local news and information available nowhere else."
http://www.cnbc.com/id/47695592
Buffett takes an interest in Lee Enterprises...
“Berkshire Hathaway is a very successful, very smart investor,” Daniel Hayes, a spokesman for Lee, said in a phone interview. “We’re gratified he’s taken an interest in Lee Enterprises and in our industry.”
http://www.bloomberg.com/news/2012-06-05/buffett-s-berkshire-discloses-stake-in-lee-enterprises.html
MUST SEE laser-projected GPS micro-display laser technology innovation...
http://pioneer.jp/carrozzeria/cybernavi/avic_vh99hud_avic_zh99hud/
----------------------------------------------------------------
PC World Article: This New GPS Does Augmented Reality, Makes You Feel Like You're in a Fighter Jet.....
http://www.pcworld.com/article/255486/this_new_gps_does_augmented_reality_makes_you_feel_like_youre_in_a_fighter_jet.html
----------------------------------------------------------------
The company will supply these units through Pioneer to japan through definite contract agreements with royalties being paid to MicroVision...
http://www.businesswire.com/news/home/20120410005638/en/MicroVision-Announces-Definitive-Agreements-Pioneer-HD-PicoP
Will come back even stronger again yet.... if it can make those kind of gains on a major market red day as we had today, IMO.
HUGE NEWS ARTICLE OUT ABOUT SGEN IN NYTIMES!!!
https://www.nytimes.com/2012/06/01/business/a-new-class-of-cancer-drugs-may-be-less-toxic.html
The New York Times
May 31, 2012
A New Class of Cancer Drugs May Be Less Toxic
By ANDREW POLLACK
Fern Saitowitz’s advanced breast cancer was controlled for about a year by the drug Herceptin and a toxic chemotherapy agent. But her hair fell out, her fingernails turned black and she was constantly fatigued.
She switched to an experimental treatment, which also consisted of Herceptin and a chemotherapy agent. Only this time, the two drugs were attached to each other, keeping the toxic agent inactive until the Herceptin carried it to the tumor. Side effects, other than temporary nausea and some muscle cramps, vanished.
“I’m able to live a normal life,” said Ms. Saitowitz, 47, a mother of two young children in Los Angeles. “I haven’t lost any of my hair.”
The experimental treatment, called T-DM1, is a harbinger of a new class of cancer drugs that may be more effective and less toxic than many existing treatments. By harnessing antibodies to deliver toxic payloads to cancer cells, while largely sparing healthy cells, the drugs are a step toward the “magic bullets” against cancer first envisioned by Paul Ehrlich, a German Nobel laureate, about 100 years ago.
“It’s almost like we’re masking the chemotherapy,” said Dr. Edith Perez, a breast cancer specialist at the Mayo Clinic in Jacksonville, Fla.
One such drug, Adcetris, developed by Seattle Genetics, was approved last August to treat Hodgkin’s lymphoma and another rare cancer. TDM-1, developed by Genentech, could reach the market next year. Data from a large clinical trial of T-DM1 is expected to attract attention at the annual meeting of the American Society of Clinical Oncology this weekend in Chicago.
Numerous other companies, from pharmaceutical giants to tiny start-ups, are pursuing the treatments, which are known variously as antibody-drug conjugates, armed antibodies or empowered antibodies. “I don’t think there is a major pharma or a midsized pharma with interest in cancer that doesn’t have a program or isn’t scrambling to put one together,” said Stephen Evans-Freke, a managing general partner at Celtic Therapeutics, an investment firm that recently committed $50 million to create a new company, ADC Therapeutics, to develop antibody-drug conjugates.
About 25 such drugs from a variety of companies are in clinical trials, according to Alain Beck, a French pharmaceutical researcher who closely tracks the field. Genentech alone has eight in clinical trials besides T-DM1, and another 17 in earlier stages of development.
Many of the drugs use technology from either Seattle Genetics, based in Bothell, Wash., or ImmunoGen of Waltham, Mass., which supplied the toxin and linker used in T-DM1....
Continued in Part 2
In one trial involving 137 women, including Ms. Saitowitz, T-DM1 proved both more effective and less toxic than a combination of Herceptin and the chemotherapy drug docetaxel as an initial treatment for metastatic breast cancer.
Those who received T-DM1 went a median of 14.2 months before their disease worsened, compared with 9.2 months for those getting the two-drug combination. Yet only 46 percent of the T-DM1 patients suffered a severe side effect, half the rate of the other group.
At the cancer conference, researchers will present results of a pivotal trial involving nearly 1,000 women. Though armed antibodies are easy to envision, it has taken more than three decades to make them practical, with many failures along the way.
With the first armed antibody to reach the market, Mylotarg, the toxin sometimes fell off the antibody prematurely, causing side effects. Approved in 2000 to treat acute myeloid leukemia, Mylotarg was removed from the market by its manufacturer, Pfizer, in 2010 after new studies showed it did not prolong lives and had safety problems.
Since then, two antibodies linked to radioactive isotopes have been approved to treat non-Hodgkin’s lymphoma — Bexxar from GlaxoSmithKline and Zevalin from Spectrum Pharmaceuticals. These drugs, while effective, are more cumbersome to use than antibodies linked to chemical toxins.
Researchers first tried to use existing chemotherapy drugs as the payloads, but they were simply not toxic enough. That is because less of a drug gets to the tumor when carried on an antibody than when the drug floods the body by itself.
Seattle Genetics and ImmunoGen use toxins that are hundreds of times as potent as typical chemotherapy agents. They are too toxic to be given by themselves.
The linkers have proved even tricker to develop since they must keep the toxin attached to the antibody while in the bloodstream, but then release the toxin inside the cancer cell.
Dr. John Lambert, executive vice president for research and development at ImmunoGen, will be in the audience at the cancer conference as the fruits of 30 years of work are presented.
“To get to this point is an indescribable feeling, actually,” he said.
GNOM is a Buyout Target Candidate !!! This will run....
Complete Genomics Inc. (GNOM) facts:
Swiss giant corporation Roche made a hostile offer to buy Illumina Inc. for $5.7 billion. There are more drugmakers “fishing” for an acquisitions in the “DNA space” such as Danaher Corp., Thermo Fisher Scientific Inc. or Agilent Technologies Inc. Complete Genomics Inc. (GNOM) is a potential buyout target for them.
GNOM revenues are at about $21 million in 2011, and are expected to surge to about $37 million in 2012.
GNOM has about $105M cash in hands versus $23.6M in debt
GNOM has enough cash to avoid secondary offering in mid-term – dilution is not expected
GNOM traded below its book value
GNOM has free trading count below 18M shares with short interest of over 25% (quarter of the all floating shares) – short squeeze is imminent on any buyout announcement.
GNOM has enough space to run: its 52Week ranges are from $2.21 to $18.55
http://pennystockhaven.com/complete-genomics-inc-gnom-buyout-target-candidate/
Leg up?
See how this technology is already in use at Drexel University in Philadelphia, PA.
http://dutv.drexel.edu/television/friday.html
Facebook IPO and Renn Renn
Article below talks about a good entry point before the Facebook IPO is out. THIS LOOKS LIKE IT COULD BE IT! IMO
https://community.tradeking.com/forum/categories/general/topics/8524-facebook-ipo-and-renn-renn/forum_posts
PART 3 - THE BEST IS YET TO COME
Will spike up EOD. IMO
NEXT WEEK = EAT YOUR SHORTS
Promotional newsletters efforts of SNPK continues - $2 again?
"We plan on continuing to cover SNPK for weeks to come because we still believe in it as strongly as ever, and we feel that there could be MUCH MORE to come!"
http://thestockmarketwatch.com/newsletters/2012/04/18/snpk-announces-clotamin-to-be-available-at-60-walgreens-in-philadelphia-3/
"T" Trade Details After Hours
Time/Price/Share Volume
16:07/$1.50/5,000
16:00/$0.93/2,000
16:00/$0.925/2,500
16:00/$0.93/2,000
16:00/$1.06/23,554
16:00/$0.93/201,262
16:00/$0.93/4,000
16:00/$1.9406/2,922,050
Read more: http://www.nasdaq.com/symbol/snpk/after-hours#ixzz1sQTLTZTY
Will ride back up tomorrow. 3M+ purchase at close.
Get back on the train before power hour arrives.
Buy back on dips!! If they wait for you!!!
Off to the races!!!!!
Off to the races!!!!!
Only low volume sales on ask so far
Vanishing debt. There is already big money for COIN in VRNG by virtue of their investment in IP. I/P shares owned by COIN wll convert into VRNG shares which today would amount to over $3M, and will continue to rise if the PPS of VRNG does and the merger happens. Company will be back on it's feet again because of this deal. We are a multi-bagger in process!!
Quote:
_________________________________________________
mrjic
If VRNG merges as expected with IP, Cuban will have a big stake in the outcome of the patent lawsuit against Google et al., and if you don't think that that is a big factor as to why he invested you are a fool. The merger is going through. The impact on COIN is that if Cuban invested he must think the lawsuit has merit and COIN is already a party to that suit by virtue of their investment in IP. The reason COIN stands to move up with VRNG at this point (pre-merger) is that most people are assuming that the merger is going to happen.
________________________________________________
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=74383276
Stock price will increase due to VRNG shares held by COIN. Settlements taking the company out of debt. This will ride high alongside VRNG. Watch and see. $$$$
Qoute:
_________________________________________________
The Rainmaker
Share
Sunday, April 15, 2012 9:49:01 AM
Re: runningwithscissors post# 8437
Post # of 9359 (http://investorshub.advfn.com/boards/read_msg.aspx?message_id=74405753)
Good luck this week everyone, hope you do well
_________________________________________________
Got COIN?
This penny stock company, Converted Organics (COIN), bought 452,000 shares of Vringo (VRNG) now worth $1,735,680 at $3.84 (as of 4/17/12 market close). Current PPS is at $0.0226 and it is expected to become a multi-bagger (...can you say triple?).
See details about COIN involvement here:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=74508018
COIN interest in Innovate/Protect merger agreement with Vringo
"On March 15, 2012 Converted Organics filed a Current Report on Form 8-K with the SEC announcing that we had acquired 150 shares of Preferred Stock of Innovate Protect, Inc."
Innovate/Protect announced on March 14, 2012 "....that it has entered into a merger agreement with Vringo, Inc. (NYSE Amex: VRNG), a provider of software platforms for mobile social and video applications.
If the merger is consummated, subject to the terms of the merger agreement, the shares of Innovate/Protect owned by Converted Organics Inc. will be converted into 452,640 shares of common stock of Vringo, as well as approximately 181,000 warrants to purchase shares of Vringo common stock at an exercise price of $1.76 per share (subject to adjustment)."
http://ir.convertedorganics.com/releasedetail.cfm?ReleaseID=660441
Also see:
http://finance.yahoo.com/news/vringo-innovate-protect-sign-definitive-110000967.html
Additionally:
Press release says they bought 452,000 shares of Vringo (VRNG) now worth $1,735,680 at $3.84.
"Innovate/Protect announced yesterday that it has entered into a merger agreement with Vringo, Inc. (NYSE Amex:VRNG), a provider of software platforms for mobile social and video applications. If the merger is consummated, subject to the terms of the merger agreement, the shares of Innovate/Protect owned by Converted Organics Inc. will be converted into 452,640 shares of common stock of Vringo, as well as approximately 181,000 warrants to purchase shares of Vringo common stock at an exercise price of $1.76 per share (subject to adjustment)."
"On March 13, 2012, we completed an additional closing pursuant to the purchase agreement we entered into on January 3, 2012, in which we issued convertible notes having an aggregate original principal amount of $550,000 for a purchase price of $500,000, and warrants to purchase an aggregate of 2,619,048 shares of common stock at an exercise price of $0.105 per share. Additional information regarding this transaction is set forth in the Form 8-K we filed yesterday."
Shares outstanding at the time were subject to the 500:1 reverse split.
http://www.knobias.com/story.htm?eid=3.1.cf92170fef1b276ffd6b2ff394...
Looks like a safe place to stay parked for a while.
Coming back now.
It's following VRNG, check it out.
We have lift-off!!!!
Here we go!
CUBAN on CNBC about VRNG, we will follow same uptrend as VRNG in coming days.
Gonna Fly Tomorrow!!! Only 38,449,292 shares outstanding vs. today's volume being of 113,000,435 shares traded. Sweet!!!!
http://www.thestreet.com/quote/COIN/details/advanced-charts.html
Panicking flippers are taking this down this morning. They are making heavy volume buys and sells and when the price falls below their purchased price they are unloading all at once at low prices, thus driving the PPS further down. Hang on to your shares!!!
http://www.trade4all.com/view_newsletters.php?email_id=41391&thetitle=Flippin'++Friday!&desc=...
Going ballistic!
Up, up & away!! Here we go, all!!!
Stage 3 should be next week or early the week after
Bogus Rumor Dispelled.
Per MrKrimes:
Call 718-715-8770 and ask for a gentleman by the name Steven Weiss (Viacom)
Quote:
______________________________________________________________
China-based pharmaceutical manufacturer China Health Resource Inc. today opened an office in Princeton and appointed Steven Weiss, a financial media veteran from CBS Television and Viacom, as head of its strategic financial marketing and investor relations program in the United States.
__________________________________________________________________
Per subslover:
"....I spoke to another Steven that works there,(Don't know his last name) the other guy was out on business. I even asked him this "how are things going with the HBRM acquisition" and his answer "going very well and stage 3 should be next week or early the week after sometime"
See this post on IHUB forum for CHRI:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=74255848
Thanks MrKrimes!
Screamin' bounce play tomorrow! Get your shares early before it's too late!! GLTA
Gap up already showing on Scottrade
Bid/Size 0.0066 / 5,000
Ask/Size 0.0072 / 5,000